Igor D. Grachev - Concepedia

Author

Igor D. Grachev

Also Known As

CEMI RAS, I D Grachev, I GRACHEV, I. D. Grachev, I. Grachev, I.D. Grachev, IGOR D. GRACHEV, Igor D Grachev, Igor D. Grachev, Igor Grachev

122

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

SUNY Upstate Medical University Massachusetts General Hospital Teva Pharmaceuticals (United States)United States Military Academy Northwestern University

About

Igor D. Grachev is an author at SUNY Upstate Medical University specializing in neuroscience, medicine, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	20	1.8K
2	Social Sciences	12	12	1.1K
3	Health Sciences	4	4	295
4	Cognitive Science	3	3	96
5	Kinesiology	1	1	39

Igor D. Grachev

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density Craig Curtis, José E. Gámez, Upinder Singh, JAMA Neurology	2015	329
Abnormal brain chemistry in chronic back pain: an in vivo proton magnetic resonance spectroscopy study Igor D. Grachev, Bruce E. Fredrickson, A. Vania Apkarian Pain Abnormal Brain ChemistryPain SyndromeNeurophysiologyPain MedicineNeuroanatomy	2000	290
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR Dean F. Wong, Hiroto Kuwabara, Andrew G. Horti, NeuroImage Cannabis UseNeuropsychologyPsychoactive DrugNovel Pet RadioligandPsychiatry	2010	202
Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging Richard O’Sullivan, Scott L. Rauch, Igor D. Grachev, Biological Psychiatry NeuropsychologyBasal GangliaPsychiatryBasal Ganglia VolumesNeuroanatomy	1997	169
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study Tanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, The Lancet Neurology Dopamine TransporterParkinson DiseaseNeuroscienceNeurologyDopamine	2019	135
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo Koen Van Laere, Cindy Casteels, Sophie Lunskens, Neurobiology of Aging Cannabis UseType 1Functional SelectivityMedicineNeuropharmacology	2011	119
Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo Koen Van Laere, Cindy Casteels, I. Dhollander, Journal of Nuclear Medicine	2010	115
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study Ralf Reilmann, Andrew McGarry, Igor D. Grachev, The Lancet Neurology Neurodegenerative DiseasesMedicinePsychotropic MedicationPsychopharmacologyPharmacotherapy	2018	104
Chemical Heterogeneity of the Living Human Brain: A Proton MR Spectroscopy Study on the Effects of Sex, Age, and Brain Region Igor D. Grachev, A. Vania Apkarian NeuroImage Brain FunctionNeurophysiologyNeuroanatomyBrain DevelopmentLiving Human Brain	2000	101
A Method for Assessing the Accuracy of Intersubject Registration of the Human Brain Using Anatomic Landmarks Igor D. Grachev, D. Berdichevsky, Scott L. Rauch, NeuroImage NeuropsychologyNeuroimaging ModalityNeuroanatomyImage RegistrationBrain Mapping	1999	94

Page 1